Loviride

Short description: Chemical compound

Loviride

Clinical data
Other names| R089439; loveride[citation needed]
ATC code|

* None

Identifiers

IUPAC name

* 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide

CAS Number|

* 147362-57-0 N

PubChem CID|

* 3963

ChemSpider|

* 3826 Y

UNII|

* 3S1R1LZ09H

KEGG|

* D04786 Y

ChEMBL|

* ChEMBL37624 Y

Chemical and physical data
Formula| C17H16Cl2N2O2
Molar mass| 351.23 g·mol−1
3D model (JSmol)|

* Interactive image

SMILES

* Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N

InChI

* InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23) Y

* Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N Y

NY (what is this?) (verify)

Loviride is an experimental antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.[1] It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR[2] and AVANTI[3]), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.

## References

1. ↑ "Loviride". http://www.aidsmap.com/cms1032278.asp.
2. ↑ "Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial". The Lancet 349 (9063): 1413–1421. 1997. doi:10.1016/S0140-6736(97)04441-3. https://dare.uva.nl/personal/pure/en/publications/randomised-trial-of-addition-of-lamivudine-or-lamivudine-plus-loviride-to-zidovudinecontaining-regimens-for-patients-with-hiv1-infection-the-caesar-trial(60592251-8bcd-4787-8c25-b7115864937b).html.
3. ↑ "AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group". Antiviral Therapy 4 (2): 79–86. 1999. doi:10.1177/135965359900400204. PMID 10682152.

* v
* t
* e

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Entry/fusion inhibitors
(Discovery and development)|

* gp41 (Enfuvirtide (ENF, T-20))
* CCR5 (Maraviroc (MVC)
* Vicriviroc†, Cenicriviroc†, PRO 140†)
* CD4 (Ibalizumab†, UB421§)
* gp120 (Fostemsavir†)

Reverse-transcriptase
inhibitors (RTIs)|

| Nucleoside and
nucleotide (NRTI)|

* Nucleoside analogues/NRTIs: Abacavir (ABC)°#
* Didanosine (ddI)
* Emtricitabine (FTC)°
* Lamivudine (3TC)°#
* Stavudine (d4T)#
* Zidovudine (AZT, ZDV)#
* Amdoxovir†
* Apricitabine†
* Censavudine†
* Elvucitabine†
* Islatravir (EFdA)§
* Racivir†
* Stampidine†
* Zalcitabine (ddC)◊

* Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)°#
* Tenofovir alafenamide (TAF)

|

Non-nucleoside (NNRTI)
(Discovery and development)|

| 1st generation|

* Efavirenz (EFV)°#
* Nevirapine (NVP)#
* Delavirdine (DLV)◊

|

2nd generation|

* diarylpyrimidines
* Etravirine (ETR)
* Rilpivirine (RPV)°
* Doravirine°

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))|

* Dolutegravir (DTG)°
* Elvitegravir (EVG)°
* Raltegravir (RAL)°
* BI 224436†
* Cabotegravir†
* Bictegravir (BIC)†
* MK-2048†

Maturation inhibitors|

* Bevirimat†
* BMS-955176§

Protease Inhibitors (PI)
(Discovery and development)|

| 1st generation|

* Amprenavir (APV)◊
* Fosamprenavir (FPV)
* Indinavir (IDV)◊
* Lopinavir (LPV)
* Nelfinavir (NFV)
* Ritonavir (RTV)#
* Saquinavir (SQV)#

|

2nd generation|

* Atazanavir (ATV)°#
* Darunavir (DRV)°#
* Tipranavir (TPV)

Combined formulations|

* Abacavir/lamivudine°#
* Abacavir/dolutegravir/lamivudine°
* Abacavir/lamivudine/zidovudine
* Atazanavir/cobicistat
* Bictegravir/emtricitabine/tenofovir alafenamide
* Darunavir/cobicistat
* Dolutegravir/lamivudine
* Doravirine/lamivudine/tenofovir disoproxil
* Efavirenz/emtricitabine/tenofovir°#
* Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
* Elvitegravir/cobicistat/emtricitabine/tenofovir°
* Emtricitabine/tenofovir alafenamide
* Emtricitabine/rilpivirine/tenofovir alafenamide
* Emtricitabine/rilpivirine/tenofovir°
* Emtricitabine/tenofovir°#
* Lamivudine/raltegravir
* Lamivudine/zidovudine#
* Lopinavir/ritonavir°#

Pharmacokinetic boosters|

* Cobicistat (c)
* Ritonavir (r)#

Experimental agents|

| Uncoating inhibitors|

* TRIM5alpha (gene)

|

Transcription inhibitors|

* Tat antagonists

Translation inhibitors|

* Trichosanthin

Other|

* Abzyme
* BIT225†
* Calanolide A
* Ceragenin
* Cyanovirin-N
* Diarylpyrimidines
* Epigallocatechin gallate (EGCG)
* Foscarnet
* Fosdevirine†
* Griffithsin
* Hydroxycarbamide
* KP-1461†
* Miltefosine
* Portmanteau inhibitors
* Scytovirin
* Seliciclib†
* Synergistic enhancers
* Tre recombinase
* Zinc finger protein transcription factor

Failed agents|

* Aplaviroc
* Atevirdine
* Brecanavir
* Capravirine
* Dexelvucitabine
* Droxinavir
* Lasinavir
* Emivirine
* Lersivirine
* Lodenosine
* Loviride
* Mozenavir
* Palinavir
* Telinavir

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

°DHHS recommended initial regimen options. ◊Formerly or rarely used agent.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Loviride. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Loviride&oldid=3332976"
*[CID]: Compound ID
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template